We caught up with EASD President Prof. Stefano Del Prato (University of Pisa, Italy) to discuss the impact of the COVID-19 pandemic on the diabetes community and the latest emerging therapies in diabetes management.
- What have been the greatest challenges faced by the diabetes community during the COVID-19 pandemic? (0:30)
- What are the most exciting recent/emerging innovations in diabetes therapy? (2:01)
Disclosures: Stefano Del Prato has received grant/research support from AstraZeneca and Boehringer Ingelheim; has served on advisory boards for Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck & Co., Novartis Pharmaceuticals, Novo Nordisk and Sanofi; and has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck & Co., Novartis Pharmaceuticals, Novo Nordisk, Sanofi, and Takeda Pharmaceuticals.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Share this Video
Related Videos In Diabetes
Clipper Young & Shirley Wong, ADCES 2022: New horizons in type 2 diabetes management and cardiorenal risk reduction: A pharmacotherapeutic update
Cardiorenal complications in people with type 2 diabetes illustrates a link between the heart and the kidneys, which can be exacerbated by other comorbidities, such as hypertension, dyslipidaemia, and obesity. In this touchENDOCRINOLOGY interview, Dr Clipper Young and Shirley Wong (Touro University California College of Osteopathic Medicine, Vallejo, CA, USA) firstly discuss diabetes management and […]
Jennifer Clements, ADCES 2022: Efficacy and safety of once-daily vs twice-daily insulin glargine in non-critically ill patients with diabetes
In this touchENDOCRINOLOGY interview, Prof. Jennifer Clements (University of South Carolina, College of Pharmacy, Columbia, SC, USA) joins us to discuss a study investigating the efficacy and safety of once-daily vs twice-daily insulin glargine in non-critically ill patients. The abstract entitled: ‘A Retrospective Analysis of Once-daily versus Twice-daily Dosing of Insulin Glargine in Non-critically Ill […]
Jennifer Clements, ADCES 2022: Clinical implications of SGLT-2 inhibitors for chronic kidney disease in people with type 2 diabetes
Chronic kidney disease in people with type 2 diabetes is heavily prevalent, and the main causes are diabetes and hypertension. In this touchENDOCRINOLOGY interview, Prof. Jennifer Clements (University of South Carolina, College of Pharmacy, Columbia, SC, USA) joins us to discuss the health burden of chronic kidney disease (CKD) in people with type 2 diabetes, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!